XML 40 R55.htm IDEA: XBRL DOCUMENT
v3.20.1

Intangible Assets, Net - Additional Information (Detail) - USD ($) | 12 Months Ended
--- | ---
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017
Finite Lived Intangible Assets [Line Items] |  |  |
Cost of sales - amortization of intangible assets | $ 9,217,000 | $ 10,862,000 | $ 1,194,000
Impairment of intangible assets | 0 | 0 |
Merck |  |  |
Finite Lived Intangible Assets [Line Items] |  |  |
Cost of sales - amortization of intangible assets | $ 9,200,000 | 8,100,000 |
GlaxoSmithKline Biologicals SA |  |  |
Finite Lived Intangible Assets [Line Items] |  |  |
Cost of sales - amortization of intangible assets |  | 1,500,000 |
Coley Pharmaceutical Group, Inc. |  |  |
Finite Lived Intangible Assets [Line Items] |  |  |
Cost of sales - amortization of intangible assets |  | $ 1,300,000 | $ 1,200,000

X
- Definition Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(b)(2)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_CostOfGoodsAndServicesSoldAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=dvax_MerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dvax_GlaxoSmithKlineBiologicalsSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dvax_ColeyPharmaceuticalGroupIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |